Suchergebnisse - "Perrone, Francesco"

PubPharm (98)

1

Cross-cultural adaptation of the PROFFIT Instrument to measure financial toxicity in people living with cancer within a UK population

enthalten in: Journal of cancer policy | 2023

von Patel, A. | Perrone, F. | Ashcroft, D. | +3

2

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France : a phase 3, open-label, randomised controlled trial

enthalten in: Lancet (London, England) | 2023

von Chu, Q. | Perrone, F. | Greillier, L. | +32

CommentIn: Lancet. 2023 Dec 16;402(10419):2266-2267. - PMID 37931626

3

Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab

enthalten in: Clinical pharmacology and therapeutics | 2023

von Polano, M. | Bedon, L. | Dal Bo, M. | +19

4

Brief Report : Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Piccirillo, M. | Chu, Q. | Bradbury, P. | +32

CommentIn: J Thorac Oncol. 2023 Jun;18(6):e67-e68. - PMID 37210188

5

Effect of bevacizumab in advanced low grade serous ovarian cancer : Data from the MITO 22 trial

enthalten in: Gynecologic oncology | 2023

von Musacchio, L. | Turinetto, M. | Arenare, L. | +18

6

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3) : a multicentre, open-label, randomised, controlled, phase 2 trial

enthalten in: The Lancet. Oncology | 2023

von Pignata, S. | Scambia, G. | Schettino, C. | +128

CommentIn: Lancet Oncol. 2023 Mar;24(3):201-203. - PMID 37052963

7

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021

enthalten in: JAMA network open | 2023

von Ciani, O. | Meregaglia, M. | De Lorenzo, F. | +2

8

Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer

enthalten in: JAMA network open | 2022

von Bartoletti, M. | Pignata, S. | Lorusso, D. | +3

9

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer : a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

enthalten in: British journal of cancer | 2022

von Musacchio, L. | Califano, D. | Bartoletti, M. | +26

10

Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer : phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2022

von Schettino, C. | Musacchio, L. | Bartoletti, M. | +14

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]